BTBP(SH:600161)2017-04-26 16:00Financial Performance - Operating revenue rose by 45.17% to CNY 522,873,527.83 year-on-year[6] - Net profit attributable to shareholders increased significantly to CNY 99,580,736.76, compared to a loss of CNY 676,046.48 in the same period last year[6] - Basic earnings per share reached CNY 0.19, a significant increase from a loss of CNY 0.001 per share in the previous year[6] - The total profit for the period was RMB 147,619,239.12, reflecting a 375.12% increase compared to the previous year[16] - The company's net profit for Q1 2017 was CNY 120,321,575.29, compared to a net profit of CNY 12,520,065.46 in the same period last year, representing a significant increase[30] Cash Flow - Cash flow from operating activities improved by 429.11% to CNY 19,399,044.81 compared to the same period last year[6] - The net cash flow from operating activities was CNY 19,399,044.81, an increase of 429.11% due to increased sales receipts[18] - Cash inflow from operating activities totaled ¥316,392,820.95, while cash outflow was ¥169,364,789.40, resulting in a net cash inflow of ¥147,028,031.55[37] - The cash outflow from operating activities was CNY 381,171,211.96, compared to CNY 320,453,427.95 in the previous year[33] Assets and Liabilities - Total assets increased by 2.65% to CNY 5,936,569,665.57 compared to the end of the previous year[6] - Total liabilities as of March 31, 2017, were CNY 3,387,274,488.36, compared to CNY 3,342,268,058.07 at the beginning of the year, reflecting a slight increase of 1.3%[25] - The company's cash and cash equivalents decreased to CNY 619,639,753.34 from CNY 660,322,787.24[22] - Inventory increased to CNY 1,059,326,108.72 from CNY 999,977,592.13, indicating a focus on stock accumulation[23] Shareholder Information - The total number of shareholders reached 28,248 by the end of the reporting period[10] - The largest shareholder, China National Biotechnology Group Corporation, holds 53.30% of the shares[10] Government Support - The company received government research subsidies amounting to CNY 3,771,909.06, contributing to non-operating income[8] Investment Activities - The company made a significant investment of RMB 28,000,000.00 in its subsidiary Chengdu Rongsheng, enhancing its financial assets[14] - The net cash flow from investment activities was -CNY 134,273,527.06, reflecting a 129.19% increase attributed to investments in subsidiaries[18] Future Plans - The company plans to continue enhancing its product offerings and market presence, focusing on new vaccine launches and expanding its blood product line[16] - The company plans to complete the asset injection to eliminate competition with its controlling shareholder by Q4 2017[20] Cost Management - Sales expenses increased by 143.10% to RMB 32,196,536.68, attributed to increased market expansion efforts[16] - The cash paid for various taxes increased by 130.82% to RMB 57,941,458.64, driven by higher revenue leading to increased VAT and corporate income tax prepayments[17]